68 completed, 7 unknown, 5 terminated, 2 active not recruiting. 87 Phase 3, 14 Phase 2.
Follow Hyperlipidemia: new trials by email Literature Review of Hyperlipidemia trials Research Report on Hyperlipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2026-10-15 | 2026-10-22 |
| A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia SHR-1918, SHR-1918 placebo - Hyperlipidemia | Phase 3 | Recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 900 | 2026-01-13 | 2026-09-10 |
| A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037) Enlicitide, Rosuvastatin, Placebo for Enlicitide - Hyperlipidemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 996 | 2025-11-11 | 2026-09-01 |
| Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine Berberine, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Enrolling by invitation | The University of Hong Kong | 100 | 2024-08-01 | 2025-01-20 |
| A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 246 | 2022-01-26 | 2025-03-06 |
| A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 122 | 2021-11-04 | 2025-02-28 |
| A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia AK102, Placebo - Hyperlipidemia | Phase 3 | Completed | Akeso | 464 | 2021-11-03 | 2025-03-06 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C K-877 0.1 mg tablet, Fenofibrate 200 mg capsule, Placebo tablet - Hyperlipidemia | Phase 3 | Completed | Kowa Company, Ltd. | 353 | 2021-09-17 | 2025-05-23 |
| Effect of Evolocumab on Coronary Atherosclerosis Evolocumab, 18F-NaF PET, CCTA - Cardiovascular Disease, Hyperlipidemia | Phase 3 | Completed | Cedars-Sinai Medical Center | 55 | 2019-03-19 | 2024-07-17 |
| Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg, Amlodipine 10mg+Valsartan 160mg, Valsartan 160mg+Atorvastatin 40mg - Hypertension, Hyperlipidemia | Phase 3 | Unknown | HK inno.N Corporation | 180 | 2017-10-13 | 2018-08-21 |
| Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia Temisartan+Amlodipine+Rosuvastatin (Combination drug), Temisartan+Amlodipine, Temisartan+Rosuvastatin - Hypertension, Hyperlipidemia | Phase 3 | Completed | Yuhan Corporation | 202 | 2017-04-11 | 2019-01-16 |
| A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Rosuvastatin, Atorvastatin - Hyperlipidemia | Phase 2 / Phase 3 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 90 | 2016-09-01 | 2016-12-02 |
| The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production Insulin, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Completed | University Health Network, Toronto | 9 | 2016-04-14 | 2017-05-08 |
| Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia NK-104-CR, Livalo® IR, Placebo (for NK-104-CR) - Hyperlipidemia, Dyslipidemia | Phase 3 | Withdrawn | Kowa Research Institute, Inc. | 2016-02-01 | 2021-05-10 | |
| Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia NK-104-CR, Placebo, Livalo - Hyperlipidemia, Dyslipidemia | Phase 3 | Withdrawn | Kowa Research Institute, Inc. | 2016-01-01 | 2021-05-10 | |
| Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia Bococizumab 150mg, Bococizumab 75mg, Bococizumab 150mg placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 299 | 2015-06-01 | 2017-12-19 |
| Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 Atorvastatin10mg, Ezetimibe10mg, Atorvastatin10mg, Ezetimibe placebo, Atorvastatin20mg, Ezetimibe10mg - Hyperlipidemia | Phase 3 | Completed | Chong Kun Dang Pharmaceutical | 385 | 2015-03-01 | 2016-01-28 |
| Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events Bococizumab (PF-04950615; RN316), Placebo - Hyperlipidemia | Phase 3 | Completed | Pfizer | 746 | 2014-10-28 | 2018-07-31 |
| Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Metreleptin - Lipodystrophy, Diabetes | Phase 3 | Active not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 24 | 2014-10-09 | 2026-10-27 |
| A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Evacetrapib, Atorvastatin, Ezetimibe - Hyperlipidemia | Phase 3 | Terminated | Eli Lilly and Company | 366 | 2014-10-01 | 2019-10-08 |
Showing 20 of 87. Sign in to see all of them.
Hyperlipidemias (87) · Hypertension (14) · Hypercholesterolemia (13) · Diabetes Mellitus (8) · Dyslipidemias (7) · Hypertriglyceridemia (6) · Diabetes Mellitus, Type 2 (5) · Hyperlipoproteinemia Type II (5) · Obesity (5) · Insulin Resistance (4) · HIV Infections (3) · Heart Diseases (2) · Cardiovascular Diseases (1) · Coronary Artery Disease (1) · Coronary Disease (1)
Lipid Metabolism Disorders (87) · Metabolic Diseases (87) · Nutritional and Metabolic Diseases (87) · Dyslipidemias (80) · Cardiovascular Diseases (16) · Vascular Diseases (16) · Glucose Metabolism Disorders (15) · Endocrine System Diseases (13) · Pathological Conditions, Signs and Symptoms (6) · Body Weight (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Diabetes Mellitus (5) · Genetic Diseases, Inborn (5) · Hyperinsulinism (5) · Hyperlipoproteinemias (5)
Atorvastatin (22) · torcetrapib (9) · Ezetimibe (7) · Simvastatin (7) · Fenofibrate (6) · Rosuvastatin Calcium (6) · evolocumab (6) · bococizumab (5) · Ezetimibe, Simvastatin Drug Combination (3) · Niacin (3) · Tea (3) · Amlodipine (2) · Atazanavir Sulfate (2) · Cellulose (2) · MK-0524 (2)
Pfizer (14) · Merck Sharp & Dohme LLC (6) · Amgen (5) · Akeso (3) · Chonbuk National University Hospital (3) · Hanmi Pharmaceutical Company Limited (3) · Solvay Pharmaceuticals (3) · Abbott (2) · Kowa Research Institute, Inc. (2) · Organon and Co (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · Taipei City Hospital (2) · University Health Network, Toronto (2) · Yuhan Corporation (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1)
United States (37) · South Korea (19) · Canada (18) · France (10) · Australia (9) · South Africa (9) · Taiwan (9) · Germany (8) · Netherlands (8) · United Kingdom (8) · Czechia (7) · Spain (7) · China (6) · Denmark (6) · Hong Kong (6)
Abbas Delazar, PhD (1) · Ali Eskandari, MD (1) · Andrew R Zolopa (1) · Angel Brea, MD (1) · Barbara C Tilley, PhD (1) · Benjamin G Druss, MD MPH (1) · Byeong Hee Oh, M.D (1) · Chang-Gyu Park, Medicine (1) · Chang-Hsun Hsieh, M.D. (1)
PMID 28304227, PMID 37994400, PMID 29685591, PMID 35277540, PMID 37658997, PMID 17387129, PMID 17387131, PMID 17407645, PMID 18468736, PMID 19029466, PMID 19029469, PMID 19328244, PMID 19576324, PMID 19952712, PMID 20019677, PMID 20228610, PMID 20435205, PMID 20645885, PMID 21291812, PMID 21613319, PMID 23431291, PMID 23816039, PMID 24098467, PMID 24584549, PMID 24614112, PMID 24961447, PMID 25027585, PMID 25057276, PMID 25084280, PMID 26093535, PMID 27039291, PMID 27742464, PMID 28324110, PMID 28412650, PMID 28751575, PMID 29150250, PMID 29673890, PMID 30400924, PMID 31145045, PMID 31529318, PMID 32937023, PMID 33078867, PMID 34486528, PMID 35471192, PMID 35654771, PMID 39098034, PMID 40178463, PMID 41832848
2005 (1), 2014 (1), 2025 (1), R01MH070437 (1), R18DK067495 (1)